Paul Feuerstadt, MD: RBX2660 and FMT for C Difficile Infections

Video

It can be challenging to find a suitable donor for fecal microbiota transplantation.

While effective for treating Clostridioides difficile infections (CDI), it can be a challenge to find suitable donors for fecal microbiota transplantation (FMT).

Fecal microbiota transplantation is a procedure where healthy donor stool is infused to rectify the recipient’s intestinal microbial community by introducing micro-organisms associated with a health state to normalize microbiota composition and function.

There are plenty of reasons why potential FMT donors are ultimately rejected, including inability to come back for regular and long-term donation, high body mass index, underlying chronic illness or on long-term medications , being healthcare professionals, and the use of antibiotics within 3 months.

However, RBX2660 could be a viable option that does not rely on donor stool.

In data presenting at the 2021 American College of Gastroenterology (ACG) Annual Meeting, investigators found high clinical efficacy in reducing rCDI with a sustained clinical response up to 6 months, with consistent safety results from previous clinical trials.

In an interview with HCPLive®, Paul Feuerstadt , MD, Yale University School of Medicine, explained why RBX2660, if approved, would be a viable alternative to FMT.

Feuerstadt also discussed what the next steps are in studying the safety and efficacy of RBX2660.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.